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ABSTRACT
Vasculitides that affect the lung represent a diverse group of diseases with various
systemic clinical manifestations, and include microscopic polyangiitis (MPA), granuloma-
tosis with polyangiitis (GPA, formerly Wegener granulomatosis), Churg-Strauss syndrome
(CSS), and anti-glomerular basement membrane (anti-GBM) disease (Goodpasture syn-
drome). The etiologies of these diseases remain largely unknown. Although the pathogenic
mechanisms of each differ, these diseases overlap by the presence of anti-neutrophil
cytoplasmic autoantibodies in the vast majority of patients with MPA and GPA, and a
substantial minority of patients with CSS and anti-GBM disease. This article reviews the
current understanding of the pathogenesis of these four disease entities.
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Vasculitides that affect the lung represent a
diverse group of diseases with various systemic clinical
manifestations. Phenotypically, these diseases present
primarily with one of two, sometimes overlapping,
manifestations. Microscopic polyangiitis (MPA) and
anti-glomerular basement membrane (anti-GBM) dis-
ease (Goodpasture syndrome) typically present with
alveolar capillaritis and pulmonary hemorrhage (associ-
ated with pulmonary infiltrates), whereas granulomatosis
with polyangiitis (GPA, formerly Wegener granuloma-
tosis)1 and Churg-Strauss syndrome (CSS) are charac-
terized by granulomatous inflammation presenting with
pulmonary nodules and/or cavities and upper airway and
bronchial lesions leading to stenosis (GPA) and severe
asthma (CSS). Despite their phenotypic and different
underlying pathogenetic mechanism, these disease
entities share a common link with the presence of anti-
neutrophil cytoplasmic autoantibodies (ANCAs), which
are found in 90% of patients with MPA or GPA,
40% of patients with CSS,2,3 and 30% of patients with
anti-GBM disease.4 This article reviews the current
understanding of the pathogenesis of these four disease
entities. The pathogenesis of immune-complex-medi-
ated vasculitis associated with pulmonary manifestation





The pathogenesis of small-vessel-vasculitis associated
with the presence of ANCA is not fully understood.5,6
There is convincing evidence that ANCAs are directly
involved in the pathogenesis of pauci-immune small-
vessel vasculitis or glomerulonephritis based on substan-
tial in vitro and in vivo data. In vitro, ANCAs have been
shown to activate normal human polymorphonuclear
leukocytes.7–9 The current hypothesis stipulates that
ANCAs induce a premature neutrophil respiratory burst
and degranulation of primary and secondary granules10,11
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at the time of their margination and diapedesis, leading to
the release of lytic enzymes and toxic oxygen metabolites
at the site of the vessel wall, thus leading to endothelial
cell damage12,13 and necrotizing inflammatory injury. In
order for anti-myeloperoxidase (anti-MPO), or anti-
proteinase-3 (anti-PR3), to interact with their corre-
sponding antigens, they must penetrate the cell; alter-
natively the antigens must translocate to the cell surface.
Indeed, small amounts of cytokines [eg, tumor necrosis
factor (TNF) and interleukin-1 (IL-1)] at concentrations
too low to cause full neutrophil activation, induce the
translocation of MPO and PR3 to the cell surface.14,15
Furthermore, patients with ANCA disease aberrantly
express PR3 and MPO genes through epigenetic mech-
anisms, and this expression correlates with disease activ-
ity.16,17
In addition, PR3 and MPO released from neu-
trophils and monocytes enter endothelial cells and cause
cell damage. PR3 entry into the endothelial cells18,19
results in the production of IL-820 and chemoattractant
protein-1 and induces an apoptotic event.21,22 MPO can
transcytose intact endothelium to localize within the
extracellular matrix23 where it catalyzes nitration of
tyrosine residues on extracellular matrix proteins,24 re-
sulting in their fragmentation.25 Recent data suggest
that endothelial cells inhibit superoxide generation by
ANCA-activated neutrophils, and that endothelial cell
injury may be mediated by serine proteases instead.26
Neutrophil activation by ANCAs is likely medi-
ated by both the antigen-binding portion of the auto-
antibodies [F(ab’)2] and the engagement of their Fc
fraction to Fc gamma receptors on the surface of neu-
trophils. Engagement of the Fc receptors results in
neutrophil activation including respiratory burst, degra-
nulation, phagocytosis, cytokine production, and upre-
gulation of adhesion molecules.13,27 ANCAs have been
shown to engage both Fc gamma RIIa and Fc gamma
RIIIb receptors.28–30 In addition, ANCAs F(ab0)2 in-
duce oxygen radical production28 and the transcription
of cytokine genes in normal human neutrophils and
monocytes.31 Overall, ANCAs F(ab0)2 are likely capable
of low-level neutrophil and monocyte activation,
whereas the Fc portion causes leukocyte activation
once the F(ab0)2 has interacted with the antigen, either
on the cell surface or in the microenvironment.13
The role of T cells in the pathogenesis of pauci-
immune necrotizing small-vessel vasculitis is suggested
by the presence of CD4þT cells in the granulomatous
and active vasculitic lesions,32–35 and by correlation of
soluble markers of T cell activation with disease activity,
specifically soluble interleukin-2 receptor36 and sCD30.37
A substantial body of work examined T cell
abnormalities in ANCA disease, primarily in Wegener
granulomatosis.38 Studies indicate there can be general-
ized leukopenia with low numbers of CD4þT helper
cells independent of therapy, increased effector memory
T cells in remission, a skewing toward more PR3-
responsive Th17 cells,39 and perhaps a functional defect
in regulatory T (Treg) cells whereby these cells were
found to have diminished or absent suppression of
autologous responder T cell proliferation in co-incuba-
tion studies.40 In addition, there is an increased percent-
age of T cells secreting IL-17 in the periphery and serum
levels of TH17-associated cytokine IL-23 correlate with
the propensity for disease activity.41
Recent animal models have provided direct evi-
dence of the pathogenic role of ANCAs in small-vessel
vasculitis and helped elucidate involved inflammatory
pathways. Rats immunized with human MPO develop
anti-rat-MPO antibodies, a necrotizing and crescentic
glomerulonephritis, and pulmonary capillaritis.42 Using
intravital microscopy, elegant studies have shown that
anti-MPO-activated neutrophils marginate and diaped-
ese along the vascular wall.42 In another model, MPO
knockout mice were immunized with murine MPO, and
splenocytes from these mice were transferred to im-
mune-incompetent Rag’2 mice resulting in the develop-
ment of anti-MPO antibodies, a severe necrotizing and
crescentic glomerulonephritis, and, in some animals,
vasculitis in the lung and other organs. The transfer of
anti-MPO antibodies alone induces a pauci-immune
necrotizing and crescentic glomerulonephritis thus es-
tablishing the ability of anti-MPO antibodies to induce
disease.43,44 The disease is abrogated when the neutro-
phils of anti-MPO recipient mice are depleted by a
selective anti-neutrophil monoclonal antibody thus in-
dicating the important role of neutrophil in the patho-
genesis of this disease.45 Conversely, the transfer of T
cells alone did not cause glomerular crescent formation
or vascular necrosis.46 Using this same model, a previ-
ously unsuspected role of complement activation was
demonstrated. Glomerulonephritis and vasculitis were
abrogated with cobra venom factor and failed to develop
in mice deficient for complement factors C5 and B,
whereas C4-deficient mice developed disease compara-
ble with wild-type mice.47 These results indicate that the
alternative complement pathway (but not the classic or
lectin pathways) is required for disease induction. Fur-
thermore, the glomerulonephritis is completely abro-
gated or markedly ameliorated by treating the mice
with a C5-inhibiting monoclonal antibody.48 These
results are corroborated by in vitro experiments that
demonstrate that blockade of the C5a receptor on
human neutrophils abrogated their stimulation.49 In
aggregate, these results suggest an important role of
complement activation in the pathogenesis of ANCA
vasculitis; however, their relevance to disease in humans
remains to be established.
Animal models establishing the pathogenic role
of anti-PR3 are less well established. In a recent study,
autoimmunity-prone non-obese diabetic (NOD) mice
were immunized with recombinant mouse PR3 that





































resulted in high levels of c-ANCA, but no detectable
disease development. When splenocytes from these
immunized mice were transferred into immunodeficient
NOD–severe combined immunodeficiency (SCID)
mice, the recipient mice developed vasculitis and severe
segmental and necrotizing glomerulonephritis. How-
ever, no disease was observed when splenocytes from
rmPR3-immunized C57BL/6 mice were transferred
into immunodeficient C57BL/6-RAG-1–/– mice, sug-
gesting that complex host factors play a role in the
development of anti-PR3 mediated vasculitis.50
Induction of ANCAs
As is true for most autoimmune responses, the inciting
events in the loss of tolerance and the generation of
ANCAs are not known. Although genetic predisposi-
tions51 and environmental exposure52 have been impli-
cated, no direct link between these exposures and the
formation of ANCAs has been established. Three hy-
potheses have been advanced possibly leading to the
generation of ANCAs.
A serendipitous finding in ANCA vasculitis led to
a theory of autoantigen complementarity.53 This theory
rests on evidence that proteins transcribed and translated
from the sense strand of DNA bind to proteins that are
transcribed and translated from the anti-sense strand of
DNA. It has been demonstrated that some patients with
PR3- ANCA harbor antibodies to an antigen comple-
mentary to the middle portion of PR3. These anti-
complementary PR3 antibodies form an anti-idiotypic
pair with PR3-ANCA. Moreover, cloned complemen-
tary PR3 proteins bind to PR3 and function as a serine
proteinase inhibitor. Preliminary data suggest that the
complementary PR3 antigens are found on a variety of
microbes, some of which have been associated with
ANCA vasculitis and also found in the genome of
some patients with both PR3- and MPO-ANCA.54
Although these studies need to be confirmed and ex-
panded to determine the source of the complementary
PR3 antigen and their role (if any) in inducing vasculitis,
they provide a novel venue for understanding the prox-
imate cause of the ANCA autoimmune response.
A second theory for the genesis of ANCA disease
is based on the observation that some patients with both
MPO-ANCA and PR3-ANCA have antibodies to
another neutrophil protein, lysosome-associated mem-
brane protein 2 (LAMP2), that are capable of neutrophil
activation and endothelial damage in vitro.55 LAMP2
has homology to a protein expressed by fimbriated
bacteria (FimH). Antibodies to either FimH peptides
or LAMP2 peptides are capable of inducing necrotizing
and crescentic glomerulonephritis in rats. Anti-LAMP2
antibodies could therefore result from molecular mimi-
cry as a result of infection with gram-negative organisms
making FimH. The association of LAMP2 antibodies
with ANCA disease has not yet been independently
confirmed.
A third proposed theory of causation rests on the
concept of so-called neutrophil extracellular traps
(NETs), consisting of chromatin fibers released by
ANCA-stimulated neutrophils, and containing the
ANCA antigens MPO and PR3, as well as a neutro-
phil-derived activator of plasmacytoid dendritic cells.56
Although not specifically implicated in inducing
ANCA, this paradigm proposes a mechanism by which
the formation of NETs could activate dendritic cells and
autoreactive B cells, capable of perpetuating the auto-
immune response to the ANCA target antigens.
Churg-Strauss Syndrome
Churg-Strauss syndrome (CSS) is characterized by the
presence of eosinophil-rich granulomatous inflamma-
tion involving the respiratory tract, and a necrotizing
vasculitis involving primarily the small and medium-size
vessels. It is clinically characterized by the presence of
asthma and peripheral blood eosinophilia and allergic
rhinitis. Only 40% of patients have circulating AN-
CAs, which, when present, are usually directed against
MPO (MPO-ANCA). ANCA-positive and -negative
CSS appear to differ to some extent with regard to the
frequency and character of organ involvement. ANCA-
positive patients are more likely to manifest signs of
necrotizing glomerulonephritis, pulmonary hemorrhage,
peripheral neuropathy, and purpura, whereas ANCA-
negative patients are more likely to present cardiac
involvement and pulmonary infiltrates.3,57
ETIOLOGY
Like other vasculitides, the etiology of CSS is largely
unknown. Proposed potential triggers of disease have
included desensitization treatment, inhaled antigens,
free-base cocaine, and the use of leukotriene receptor
antagonists (LTRAs). When analyzed, only 23% of
patients with CSS had a potential triggering factor.3
Numerous reports have associated the onset of CSS with
the use of LTRAs, including reports to the Committee
on Safety of Medicines in the United Kingdom and the
U.S. Food and Drug Administration (FDA) Adverse
Event Reporting System (AERS) database in the United
States.58,59 A case-crossover study reported significantly
increased risk of developing CSS with LTRA use,60 but
this risk was not confirmed in a case-control study after
controlling for other asthma drug use by multivariate
analysis.61 It is, however, unclear whether this associa-
tion is causal, or confounded by the indication for the use
of LTRA. At stake is whether CSS may be caused by
LTRAs, whether they unmask an underlying disease by
allowing a reduction in the dose of corticosteroids, or
whether they are prescribed to patients with severe
asthma representing an early phase of the disease.





































Upon careful review of all cases of suspected drug-
induced CSS reported to the FDA between 1996 and
2003 (n¼ 1274), the diagnosis could be confirmed in
181 cases, 90% of whom had a preceding exposure to
LTRA.62 A positive ANCA test was detected in 42% of
the cases tested. Of 140 cases for whom there was
sufficient documentation to categorize the patterns of
disease presentation and corticosteroid use, 9% had a
previous diagnosis of CSS, corticosteroids were de-
creased or stopped within 6 months in 19%, 8% were
possibly in a prodromal early phase of CSS at the time
the LTRA was initiated, 20% had unstable asthma at the
time of treatment initiation, and 44% had stable asthma
at treatment initiation.62 The latter two categories sug-
gest that the use of LTRA may be causative of CSS in
some patients.
PATHOGENESIS
Understanding the pathogenesis of CSS has focused on
mechanisms involved in the development of the eosino-
philia characterizing this disorder, and notably a key role
for IL-5 and other Th2 cytokines.63 Patients with active
CSS appear to have elevated plasma levels of IL-5,64 and
peripheral blood mononuclear cell production of IL-5
may be increased in vitro in the setting of T cell
activation.63 IL5 induces terminal differentiation of
committed eosinophil precursors,65 prolongs their sur-
vival,66,67 induces their degranulation and antibody-
depended cytotoxicity,68,69 and promotes their adhesion
to endothelial cells and transmigration from the vascu-
lature.70 In addition to IL-5, T cells from patients with
CSS exhibit increased production of Th2 cytokines IL-4
and IL-13.71 Migration of eosinophils to inflammatory
sites appears to be mediated by eotaxin-3,72 and in-
creased levels of this cytokine appear to be correlated
with levels of disease activity and inflammation.73
Peripheral T cell lines from CSS patients also
produce high amounts of the Th-1 cytokine gamma-
interferon (IFNg).63 One study revealed that patients
with CSS exhibit decreased CD4þCD25þT cells that
produce IL-10 when compared with chronic eosino-
philic pneumonia and asthma, which increased in pa-
tients with CSS in remission. These findings again
suggest a role of T regulatory cells in the development
of the disease.74 It is conceivable that the relative
importance of Th-1 and Th-2 responses may differ in
patients with predominantly eosinophilic/allergic phe-
notype versus vasculitic/granulomatous manifestations
of the disease. In addition, patients with active CSS
exhibit decreased frequency of peripheral Treg cells75
and increased frequency of Th17 cells when compared
with patients with asthma and chronic eosinophilic
pneumonia.74 These findings were reversed in patients
with inactive disease.
Genetic predisposition to the development of
CSS has been proposed. In one study, HLA (human
leukocyte antigens) -DRB4 and HLA-DRB1*07 were
more prevalent among patients with CSS, with HLA-
DRB4 correlating with the number of vasculitic mani-
festations.76 In another study, three single nucleotide
polymorphisms tagging a haplotype of the IL-10 gene
promoter that were found to be highly significantly
associated with ANCA-negative CSS (n¼ 103) (odds
ratio 2.16, 95% confidence interval 1.52–3.06), but were





Goodpasture syndrome is characterized by circulating
antibodies to the GBM (anti-GBM) and deposition of
immunoglobulin G (IgG) or rarely IgA along GBMs.78,79
Anti-GBM disease occurs as a renal-limited disease
(anti-GBM glomerulonephritis) and as a pulmonary-renal
vasculitic syndrome (Goodpasture syndrome).80 The
incidence of anti-GBM disease has two peaks with respect
to age.81 The first peak is in the second and third decade of
life and has a male preponderance and a higher frequency
of pulmonary hemorrhage (Goodpasture syndrome). The
second peak is in the sixth and seventh decade and has a
predominance of women who more often have renal-
limited disease.
Genetic susceptibility to anti-GBM disease is
associated with HLA DRB1*1501 and DQB*0602,82–85
supporting the hypothesis that certain class II molecules
present GBM peptides to T helper cells. This concept is
further supported by mouse models of anti-GBM disease
in which crescentic glomerulonephritis and lung hemor-
rhage are restricted to only certain MHC (major histo-
compatibility complex) haplotypes, despite the ability of
mice of all haplotypes to produce antibodies to the
noncollagenous (NC1) domain of the a3 chain of
type IV collagen.86 In addition to genetic susceptibility
based on HLA antigens, differences in susceptibility
to anti-GBM disease in mouse strains were associated
with haplotypes of the kallikrein gene family, which
encodes serine esterases implicated in the regulation of
inflammation, apoptosis, redox balance, and fibrosis.87
Antagonizing the kallikrein pathway by blocking the
bradykinin receptors augmented disease, while bradyki-
nin administration reduced the severity of anti-GBM
antibody-induced nephritis in a susceptible mouse strain.
These results suggest that kallikreins are protective dis-
ease-associated genes in anti-GBM antibody-induced
nephritis in mice.87 Similarly, study of various strains of
rats to nephrotoxic serum (rabbit anti-rat GBM serum)
has identified the duplication of the Fc gamma R3 gene
as a determinant of resistance to disease.88 Conversely,
the susceptibility of Wistar Kyoto (WKY) rats has been
linked to a polymorphism of the JunD gene, associated





































with regulation of macrophage activation.89 Whether
these findings pertain to susceptibility or severity of
anti-GBM disease in humans in unknown.
PATHOGENESIS
The landmark study by Lerner et al90 demonstrated that
antibodies eluted from kidneys of patients with Good-
pasture syndrome and injected in monkeys led to the
induction of fulminant glomerulonephritis, proteinuria,
renal failure, and pulmonary hemorrhage along with
intense staining of the GBM for human IgG.
The antigen to which anti-GBM antibodies react
is in the collagenase-resistant part of type IV collagen, the
‘‘noncollagenous domain,’’ or NC1 domain.91–93 The
antigenic epitopes are in a cryptic form because antibody
binding to the native hexameric structure of the NC1
domain is minimal but increases 15-fold when the
hexameric NC1 domain is denatured and dissociates
into dimers and monomers.94 About 90% of anti-type
IV collagen antibodies are directed against the a-3 chain
of type IV collagen95 sequestered within the a3a4a5(IV)
NC1 hexamers. In patients with anti-GBM disease who
do not have antibodies to the classic epitopes on the a 3
chain, antibodies to entactin have been detected.96
The majority of patients with anti-GBM disease
express antibodies to two major conformational epitopes
(EA: residues 17–31 and EB: residues 127–141) located
within the carboxyterminal NC1 domain of the a-3
chain of type IV collagen.97–99 Antibody levels against
a3, EA, and EB correlated with serum creatinine and
with death or end-stage renal disease (ESRD) at 1 year,
but not with sex, age, presence of ANCAs, or hemopt-
ysis.100 The stimuli leading to the formation of anti-
GBM autoantibodies are unknown; as is the mechanism
by which the normally hidden target epitopes become
accessible to circulating autoantibodies. It is presumed
that environmental factors, such as exposure to hydro-
carbons,101 tobacco smoke,102 and endogenous oxidants
can expose the cryptic Goodpasture epitopes.
About one third of patients with anti-GBM/
Goodpasture disease also have circulating ANCA, the
majority being to MPO.103,104 No differences in the
reactivity to the major Goodpasture epitopes were de-
tected between patients with anti-GBM plus ANCAs
compared with anti-GBM alone.105 It is speculated that
in patients with concomitant anti-GBM and ANCAs,
the latter may appear first and cause damage to the
GBM, thus exposing the normally hidden target epito-
pes of anti-GBM antibodies. Coexistence of ANCAs in
patients with anti-GBM antibodies is associated with
small-vessel vasculitis in organs in addition to lung and
kidney. In experimental models, antibodies to MPO
aggravate experimental anti-GBM disease.104,106
Several animal models of anti-GBM disease were
developed based on immunization with heterologous
or homologous GBM. Anti-GBM antibody–induced
injury can also be induced passively by the intravenous
injection of heterologous anti-GBM antibodies. The rat
model induced by injection of heterologous anti-GBM
has permitted the study of the roles of various inflam-
matory mediators in the development of anti-GBM
disease.107 Thus impairing leukocyte recruitment and
monocyte/macrophage glomerular infiltrate by blocking
the chemokine CXCL16 (with a polyclonal anti-
CXCL16 antiserum),108 depleting CD8(þ ) cells, or
treatment with an antibody to perforin resulted in a
significantly reduced severity of anti-GBM-induced glo-
merular injury.109 These results suggest that CD8(þ )
cells play a role in glomerular injury as effector cells, in
part through a perforin/granzyme-mediated pathway.
Although anti-GBM disease is considered a pro-
totypical antibody-mediated disease, several lines of
evidence point to an important role for T cells in the
initiation or pathogenesis of this disease. In addition to
the association with HLA class II antigens, the involve-
ment of T cells in the development of the autoimmune
response to the Col4a3NC1 is supported by studies of
T cell proliferation in response to monomeric compo-
nents of the GBM and synthetic oligopeptides.110 A
nephritogenic T cell epitope of Col4a3NC1 was dem-
onstrated to induce glomerulonephritis in WKY rats.111
Interestingly, cross-reactive peptides from human infec-
tion-related microbes could be identified that also in-
duced severe proteinuria and modest to severe
glomerulonephritis in immunized rats. One peptide
derived from Clostridium botulinum also induced pulmo-
nary hemorrhage.112
CD4þCD25þTreg cells may play an important
role in regulating the immune response in anti-GBM
disease. The transfer of Treg cells attenuates the develop-
ment of proteinuria and glomerular damage without
preventing the deposition of immune complexes in mice
that were previously immunized with rabbit IgG and
before an injection of rabbit anti-GBM serum.113 In
humans, Treg cells may explain in part the uncommon
occurrence of disease relapses, and the eventual disappear-
ance of anti-GBM antibodies in patients even without
immunosuppressant medications as peripheral GBM-
specific Treg cells emerge in the convalescent period,
while undetected at the time of acute presentation.114
The role of complement in the pathogenesis of
anti-GBM disease is evidenced by the deposition of C3
along the GBM and supported by studies of animal
models in mice and rabbits. These studies suggest that
the terminal components of complement do not play a
major part in the pathogenesis of the disease except in
leukocyte-depleted animals.115–117 Studies using the
heterologous anti-GBM model in mice rendered com-
pletely deficient of complement components C3 or C4
revealed a protective effect of C3 deficiency more than
that of C4 deficiency.118 In an ‘‘attenuated’’ mouse
model of anti-GBM using a subnephritogenic dose of





































rabbit anti-mouse GBM antibody albuminuria was ab-
sent in Fcg chain deficient and reduced in C3 deficient
mice. C1q- and C4-deficient mice did develop protei-
nuria suggestive of involvement of the alternative path-
way of complement.119 The role of Fcg receptors is also
evidenced by the occurrence of severe lung hemorrhage
in mice deficient for the inhibitory Fcg 2b receptor
treated with bovine type IV collagen.120
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